Limits...
The cost of biologics for psoriasis is increasing.

Cheng J, Feldman SR - Drugs Context (2014)

Bottom Line: Trends were assessed by calculating the percentage change in annual cost compared with the previous year.The sales-based cost of drugs was greatest for ustekinumab ($25,012), then adalimumab ($6,786) and etanercept ($6,629).Sales-based cost increased at an average of 20% per year.

View Article: PubMed Central - PubMed

Affiliation: Center for Dermatology Research, Departments of Dermatology, Winston-Salem, NC, USA.

ABSTRACT

Background: Biologic agents have revolutionized the management of psoriasis but at a higher cost compared with "traditional" agents. Cost must be considered when evaluating management options for psoriasis.

Objective: To estimate the annual cost of treatment of psoriasis using biologic agents and assess the trend over the past decade.

Methods: The cost of annual treatment paradigms for etanercept, adalimumab, and ustekinumab was estimated using the average wholesale price. Trends were assessed by calculating the percentage change in annual cost compared with the previous year. A sales-based cost of drugs was estimated using gross US sales of each drug and an estimate of the total number of patients treated based on prescription data.

Results: The cost of one year of induction and maintenance treatment was highest for ustekinumab ($53,909), followed by etanercept ($46,395), and adalimumab ($39,041). The sales-based cost of drugs was greatest for ustekinumab ($25,012), then adalimumab ($6,786) and etanercept ($6,629). Sales-based cost increased at an average of 20% per year.

Conclusion: The cost of biologic treatments for psoriasis has been increasing. Cost considerations in the management of psoriasis are likely to increase given the limited healthcare resources that are available.

No MeSH data available.


Related in: MedlinePlus

Percent change in annual cost of biologic drugs.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4295913&req=5

f2-212266: Percent change in annual cost of biologic drugs.

Mentions: The average annual rate of increase was of the same order of magnitude for all three drugs: 8.2% for etanercept, 9.2% for adalimumab, and 11.0% for ustekinumab (Figure 2).


The cost of biologics for psoriasis is increasing.

Cheng J, Feldman SR - Drugs Context (2014)

Percent change in annual cost of biologic drugs.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4295913&req=5

f2-212266: Percent change in annual cost of biologic drugs.
Mentions: The average annual rate of increase was of the same order of magnitude for all three drugs: 8.2% for etanercept, 9.2% for adalimumab, and 11.0% for ustekinumab (Figure 2).

Bottom Line: Trends were assessed by calculating the percentage change in annual cost compared with the previous year.The sales-based cost of drugs was greatest for ustekinumab ($25,012), then adalimumab ($6,786) and etanercept ($6,629).Sales-based cost increased at an average of 20% per year.

View Article: PubMed Central - PubMed

Affiliation: Center for Dermatology Research, Departments of Dermatology, Winston-Salem, NC, USA.

ABSTRACT

Background: Biologic agents have revolutionized the management of psoriasis but at a higher cost compared with "traditional" agents. Cost must be considered when evaluating management options for psoriasis.

Objective: To estimate the annual cost of treatment of psoriasis using biologic agents and assess the trend over the past decade.

Methods: The cost of annual treatment paradigms for etanercept, adalimumab, and ustekinumab was estimated using the average wholesale price. Trends were assessed by calculating the percentage change in annual cost compared with the previous year. A sales-based cost of drugs was estimated using gross US sales of each drug and an estimate of the total number of patients treated based on prescription data.

Results: The cost of one year of induction and maintenance treatment was highest for ustekinumab ($53,909), followed by etanercept ($46,395), and adalimumab ($39,041). The sales-based cost of drugs was greatest for ustekinumab ($25,012), then adalimumab ($6,786) and etanercept ($6,629). Sales-based cost increased at an average of 20% per year.

Conclusion: The cost of biologic treatments for psoriasis has been increasing. Cost considerations in the management of psoriasis are likely to increase given the limited healthcare resources that are available.

No MeSH data available.


Related in: MedlinePlus